Farmakoterapiya tyazheloy bronkhial'noy astmy
- Authors: Mironova Z.A1, Trofimov V.I1
-
Affiliations:
- Issue: No 10 (2015)
- Pages: 12-15
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287993
- ID: 287993
Cite item
Open Access
Access granted
Abstract
Bronchial asthma is one of the most common inflammatory diseases of the airways. Increasing incidence rates, growing number of severe resistant to treatment cases and unchanging mortality rates make bronchial asthma an important medical and social problem. Consequently, prevention and treatment of bronchial asthma especially its severe forms are real challenges in public health.
Keywords
Full Text
References
- Демко И.В., Толкушин А.Г., Козлов С.Н., Чучалин А.Г. Фармакоэкономический анализ использования поддерживающего противоастматического лечения. Пульмонология. 2008;4:67-71.
- Федеральные клинические рекомендации по диагностике и лечению бронхиальной астмы, 2013. http://www.pulmonology.ru/ publications/guide.php.
- Global Initiative for Asthma, All Rights Reserved. www.ginasthma.org.
- Федосеев Г.Б., Трофимов В.И., Петрова М.А. Многоликая бронхиальная астма, диагностика, лечение и профилактика. СПб.: Нордмед-Издат, 2011. 343 с.
- Leung D.Y., Bloom J.M. Update on glucocorticoid action and resistance. J. Allergy and Clin. Immunol. 2003;11:3-22.
- Leung D.Y.M., Spahn J.D., Szefler S.J. Steroid-unresponsive asthma. Respir. Crit. Care Med. 2002;23(4):387-98.
- Barnes P.J. Corticosteroid Resistance in Airway Disease. The Proceedings of the American Thoracic Society. 2004;1:264-68.
- Newton R., Leigh R., Giembycz M.A. Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung disease. Pharmacology & Therapeutics. 2010;125:286-327.
- Bjermer L. Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation. J. Allergy Clin. Immunol. 2007;120: 1269-75.
- Миронова Ж.А. Молекулярно-генетические аспекты терапевтической резистентности у больных бронхиальной астмой: Автореф. дисс. докт. мед. наук. СПб., 2012.
- Holgate S.T., Peters-Golden M., Panettieri R.A., Henderson W.R.Jr. Roles of cystenil leukot-rienes in airway inflammation, smooth muscle function,and remodeling. J. Allergy Clin. Immunol. 2003;111(l):18-34.
- Robinson D.S., Campbell D., Barnes P.J. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomized double-blind placebo-controlled trial. Lancet. 2001;357(9273):2007-11.
- Busse W., Corren J., Lanier B.Q., McAlary M., Fowler-Taylor A., Cioppa G.D., van As A., Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 2001;108: 84-190.
- Bel E.H. Severe asthma. Breathe. 2006;3(2):23.
- Adcock I.M., Barnes P.J. Molecular mechanisms of corticosteroid resistance. Chest. 2008;134:394-401.
- Baraldi E., Ghiro L., Piovan V., Carraro S., Carraro S., Ciabattoni G., Barnes P.J., Montuschi P. Increased exhaled 8 - isoprostan in childhood asthma. Chest. 2003;124:25-31.
- Ardizzone S., Maconi G., Bianchi V., Russo A., Colombo E., Cassinotti A., Penati C., Tenchini M.L., Bianchi Porro G. Multidrug resistance 1 gene polymorphism and susceptibility to inflammatory bowel disease. Inflamm. Bowel Dis. 2007;13:516-23.
- Popescu F.D. Antisense- and RNA interference-based therapeutic strategies in allergy. J. Cell. Mol. Med. 2005;9:840-53.
- Пузырев В. П., Огородова Л.М. Генетика бронхолегочных заболеваний. Под ред. А.Г. Чучалина. М.: Атмосфера, 2010. 160 с.
Supplementary files
